Raptor Pharmaceutical Begins Dosing in Phase IIb Trial of RP103 for Non-Alcoholic Steatohepatitis

Raptor Pharmaceutical announced that a first patient has been dosed in its Phase IIb clinical trial evaluating the safety and potential efficacy of RP103 as a potential treatment of non-alcoholic steatohepatitis , an advanced form of non-alcoholic fatty liver disease in children.
MarketWatch